European Archives - Page 1245 of 1619 - European Medical Journal

EMJ Hematology 7 [Suppl 1] 2019

Prof Salles provided an update on the ongoing first-line follicular lymphoma (FL) studies, demonstrating how analysis of the GALLIUM study data regarding…

Expectations and Experience: Optimising Efficacy and Maintaining Quality of Life in Follicular Lymphoma

Prof Salles provided an update on the ongoing first-line follicular lymphoma (FL) studies, demonstrating how analysis of the GALLIUM study data regarding…

“Medical Affairs has a Central Role to Play in Building Trust Between Doctors and Healthcare Stakeholders and the Pharmaceutical Industry”

Cesar Sanz Rodriguez is Associate Vice President, Medical Affairs Lead Mid-Europe (MER), Eastern Europe, Middle East & Africa (EEMEA) Regions. He spoke to us about his progression into medical affairs from a clinical background, the changing role of medical affairs in the pharma industry, and the exciting advances currently taking place in cancer treatment.

Importance of screening for early-onset colorectal cancer

RESEARCH into early-onset colorectal cancer (CRC) has found unique subgroups among younger patients and has outlined risk factors and prevalence of…

Obesity-targeting procedures can lower cancer risk in women

Obesity is a known risk factor for a multitude of cancers, including pancreatic, ovarian, and liver, and contributes to an estimated 15–20% of all cancer…

New Insights into Prostate Cancer Treatment

ANDROGEN deprivation therapy (ADT) is commonly used for the treatment of metastatic hormone sensitive prostate cancer (mHSPC)…

A New Tool for Kidney Stone Prediction

KIDNEY STONES are a painful affliction that are common in the general population, with their prevalence estimated to be 1 in 11 in the USA population…

First Genetic Marker Associated with Biliary Atresia Identified

BILIARY atresia (BA) is a hepatic condition in which bile ducts within and surrounding the liver are abnormally narrow, impeded, or missing…

Lipid Profile in Blood Predicts Fatty Liver Disease

BIOMARKERS of fatty liver disease have been discovered by a group of researchers from the University of California, California, USA and…

“For us it’s about more than just selling the products – we want to be a responsible partner in society”

Karsten Lollike is the Corporate Vice President and the Qualified Person Responsible for Pharmacovigilance (QPPV) of Global Safety at Novo Nordisk, a position he has held for 11 years. Dr. Lollike joined Novo Nordisk in 2000, working in Global Development in Haemostasis, after obtaining his medical degree and subsequently a PhD. We spoke to Dr. Lollike about his medical expertise and experience, his long-standing career at Novo Nordisk, and what working at the company means to him.